Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real‐world clinical setting
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.15804
Abstract: Apremilast (Otezla®, Celgene France), an oral phosphodiesterase-4 inhibitor, has been approved for treating moderate-to-severe chronic plaque psoriasis in adult patients failing to respond to, or having a contraindication to, or being intolerant to other systemic… read more here.
Keywords: may influence; methotrexate; influence choice; factors may ... See more keywords